monoclonal antibodies

The “orange team,” led by Buddy Creech, MD, director of the Vanderbilt Vaccine Research Program, assembles in the old Clinical Research Center space in Medical Center North on the first day of the phase 3 Moderna vaccine study this summer.
December 16, 2020

Coronavirus ‘crusaders’ spur VUMC research achievements

The development of the vaccines, monoclonal antibodies and antiviral drugs that ultimately will defeat COVID-19 wouldn’t have been possible had it not been for the unflagging and selfless efforts of a global army of research nurses, laboratory personnel, recruiters and other staff.

By Bill Snyder
December 10, 2020

Exploiting viral vulnerabilities

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.

By Bill Snyder
James Crowe Jr., MD, and colleagues are exploring how the body’s immune system gears up to fight off infection.
December 1, 2020

Vanderbilt University Medical Center’s Crowe receives 2020 “Golden Goose” Award for COVID-19 research

James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award.

By Bill Snyder
Lab manager Rachel Nargi prepares a B-cell culture during the recent “sprint” to develop an antibody-based treatment for Zika virus infection.
August 20, 2020

Study identifies antibodies that block alphaviruses

Researchers at Vanderbilt University Medical Center have identified antibodies that, in animals, block infection by alphaviruses, which can cause chronic and debilitating joint pain and arthritis and are an increasing global health concern.

By Bill Snyder
July 15, 2020

Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.

By Bill Snyder
Research assistant Mahsa Majedi loads reagent used in DNA sample preparation in the genomics lab. She is part of a team of more than a dozen people at VUMC who are “sprinting” to develop — within 90 days — an antibody-based treatment to stop the spread of the Zika virus.
July 3, 2020

Research team isolates antibodies that may prevent rare polio-like illness in children linked to a respiratory infection

Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.

By VUMC News and Communications
June 9, 2020

Vanderbilt, AstraZeneca collaborate on new COVID-19 antibody research

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.
By Bill Snyder
May 14, 2020

Antibodies eye Pacific Island “fever”

Vanderbilt Vaccine Center team isolates monoclonal antibodies against Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.
By Bill Snyder
April 30, 2020

Antibody finding raises hopes for Marburg, COVID-19 treatments

Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody “cocktails” to counter viral infection.
By Bill Snyder
April 8, 2020

Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments

Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.
By Bill Snyder
March 23, 2020

Researchers developing potential coronavirus antibody therapies

Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.
By Bill Snyder
February 6, 2020

Antibody mixture may help block Ebola virus infection

A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus.
By Bill Snyder
January 23, 2020

Antibody isolated at VUMC found to halt dengue virus

Using part of an antibody isolated at Vanderbilt that “broadly neutralizes” the human dengue virus, biologists at the University of California San Diego and colleagues have disarmed the mosquito that transmits the disabling and potentially deadly tropical infection.
By Bill Snyder
1 … 3 4 5 6 7 … 9